RxDoctor Payments Data

Kara Kozloski, DO

Family Medicine · du Bois, PANPI 1689691164

Payments from drug & device makers

$8,196in general payments, 2019–2025

Across 495 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Astellas Pharma US Inc$835
  • Pfizer$646
  • Johnson & Johnson$584
  • Lilly USA, LLC$582
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$7,76895%
  • Education$4285%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,196 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$42,087
Medicare patients
189
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase21$71,466
OzempicSemaglutide31$29,206
MounjaroTirzepatide22$26,774
EliquisApixaban20$24,784
JardianceEmpagliflozin12$13,114
ElmironPentosan Polysulfate Sodium11$10,014
FarxigaDapagliflozin Propanediol17$9,886
Tegretol XrCarbamazepine12$9,242
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen199$4,853
Lamotrigine OdtLamotrigine12$3,819
Gabapentin172$3,000
Potassium Chloride84$2,902
Morphine Sulfate ErMorphine Sulfate105$2,684
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,512
Levothyroxine Sodium190$2,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Synthroid$1,101$73,43442 claims
Novo NordiskOzempic$1,446$29,20631 claims
Lilly USA, LLCMounjaro$582$26,77422 claims
PfizerEliquis$646$24,78420 claims
Boehringer IngelheimJardiance$99$13,11412 claims
AstraZenecaFarxiga$346$9,88617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in du Bois

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →